4-Hydrazinyl-7-Methoxy-2-Methylquinoline | 49612-20-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 4-Hydrazinyl-7-Methoxy-2-Methylquinoline
• 英文别名: (7-methoxy-2-methylquinolin-4-yl)hydrazine
• CAS: 49612-20-6
• 化学式: C₁₁H₁₃N₃O
• mdl: MFCD11040534
• 分子量: 203.244
• InChiKey: GVZBRTMCELTNJQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.181
• 拓扑面积：
  60.2
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-Hydrazinyl-7-Methoxy-2-Methylquinoline 在 盐酸 、 sodium nitrite 作用下， 生成 4-Azido-7-methoxy-2-methylquinoline
  参考文献：
  名称：

  Savini; Massarelli; Pellerano, Il Farmaco, 1993, vol. 48, # 4, p. 515 - 528

  摘要：

  DOI：

文献信息

• Targeting clinically-relevant metallo-<b>β</b>-lactamases: from high-throughput docking to broad-spectrum inhibitors
  作者：Margherita Brindisi、Simone Brogi、Simone Giovani、Sandra Gemma、Stefania Lamponi、Filomena De Luca、Ettore Novellino、Giuseppe Campiani、Jean-Denis Docquier、Stefania Butini

  DOI：10.3109/14756366.2016.1172575

  日期：2016.11.1

  Metallo-beta-lactamases (MBLs) represent one of the most important and widespread mechanisms of resistance to beta-lactam antibiotics (including the life-saving carbapenems), against which no clinically useful inhibitors are currently available. We report herein a structure-based high-throughput docking (HTD) campaign on three clinically-relevant acquired MBLs (IMP-1, NDM-1 and VIM-2). The initial hit NF1810 (1) was optimized providing the broad-spectrum inhibitor 3i, which is able to potentiate the in vitro activity of cefoxitin on a VIM-2-producing E. coli strain.
• Development of antitubercular compounds based on a 4-quinolylhydrazone scaffold. Further structure–activity relationship studies
  作者：Sandra Gemma、Luisa Savini、Maria Altarelli、Pierangela Tripaldi、Luisa Chiasserini、Salvatore Sanna Coccone、Vinod Kumar、Caterina Camodeca、Giuseppe Campiani、Ettore Novellino、Sandra Clarizio、Giovanni Delogu、Stefania Butini

  DOI：10.1016/j.bmc.2009.06.051

  日期：2009.8

  A series of 4-quinolylhydrazones was synthesized and tested in vitro against Mycobacterium tuberculosis. At a concentration of 6.25 mu g/mL, most of the newly synthesized compounds displayed 100% inhibitory activity against M. tuberculosis in cellular assays. Further screening allowed the identification of very potent antitubercular agents. Compound 4c was also tested in a time-course experiment and against mtb clinical isolates, displaying interesting results. (C) 2009 Elsevier Ltd. All rights reserved.
• Bartolucci; Cellai; Di Filippo, Il Farmaco, 1992, vol. 47, # 6, p. 945 - 952
  作者：Bartolucci、Cellai、Di Filippo、Brizzi、Pellerano、Savini、Benedetto、Elia

  DOI：——

  日期：——
• Pellerano; Savini; Brizzi, Farmaco, Edizione Scientifica, 1985, vol. 40, # 7, p. 486 - 492
  作者：Pellerano、Savini、Brizzi

  DOI：——

  日期：——
• Synthesis and anti-tubercular evaluation of 4-quinolylhydrazones
  作者：Luisa Savini、Luisa Chiasserini、Alessandra Gaeta、Cesare Pellerano

  DOI：10.1016/s0968-0896(02)00071-8

  日期：2002.7

  A series of 4-quinolylhydrazones were synthesized and tested against Mycobacterium tuberculosis H37Rv. Preparation of the title compounds was achieved by reaction of 4-quinolylhydrazine and aryl- or heteroaryl-carboxaldehyde. For the most of derivatives interesting antitubercular properties were showed: two compounds (3(2) and 3(25)), identified as the most active, were tested also against Mycobacterium avium. (C) 2002 Elsevier Science Ltd. All rights reserved.